Afrezza (insulin human) Inhalation Powder + insulin degludec
ApprovedCompleted 0 views this week 0 watching💤 Quiet
Interest: 37/100
37
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Type 1 Diabetes
Conditions
Type 1 Diabetes
Trial Timeline
Mar 31, 2022 → Oct 17, 2022
NCT ID
NCT05243628About Afrezza (insulin human) Inhalation Powder + insulin degludec
Afrezza (insulin human) Inhalation Powder + insulin degludec is a approved stage product being developed by MannKind Corp for Type 1 Diabetes. The current trial status is completed. This product is registered under clinical trial identifier NCT05243628. Target conditions include Type 1 Diabetes.
What happened to similar drugs?
20 of 20 similar drugs in Type 1 Diabetes were approved
Approved (20) Terminated (0) Active (0)
Hype Score Breakdown
Clinical
20
Activity
8
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05243628 | Approved | Completed |
Competing Products
20 competing products in Type 1 Diabetes